Regorafenib is currently the preferred TKI for the treatment of advanced hepatocellular carcinoma (HCC); this drug inhibits cell proliferation and tumor malignant progression by inhibiting the phosphorylation of tyrosine residues of target proteins such as VEGFR2 [2,3]. This evidence concerns the gene KDR and neoplasm.